MX2011013060A - Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. - Google Patents

Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.

Info

Publication number
MX2011013060A
MX2011013060A MX2011013060A MX2011013060A MX2011013060A MX 2011013060 A MX2011013060 A MX 2011013060A MX 2011013060 A MX2011013060 A MX 2011013060A MX 2011013060 A MX2011013060 A MX 2011013060A MX 2011013060 A MX2011013060 A MX 2011013060A
Authority
MX
Mexico
Prior art keywords
methods
manufacture
ophthalmic formulations
same
eye
Prior art date
Application number
MX2011013060A
Other languages
English (en)
Inventor
George Minno
George W Ousler Iii
Matthew Jonathan Chapin
Mark Barry Abelson
Jakie Nice
Original Assignee
Aciex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aciex Therapeutics Inc filed Critical Aciex Therapeutics Inc
Publication of MX2011013060A publication Critical patent/MX2011013060A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Abstract

La presente invención proporciona composiciones para tratar y/o evitar signos y síntomas asociados con ojo seco y/o irritación ocular, y métodos de uso de las mismas. Tales composiciones se proporcionan en formulaciones oftálmicas novedosas que son cómodas con la colocación gota a gota en el ojo. También se proporcionan métodos de preparación.
MX2011013060A 2009-06-05 2010-06-04 Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas. MX2011013060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18443509P 2009-06-05 2009-06-05
PCT/US2010/037423 WO2010141831A1 (en) 2009-06-05 2010-06-04 Ophthalmic formulations, methods of manufacture, and methods of using same

Publications (1)

Publication Number Publication Date
MX2011013060A true MX2011013060A (es) 2012-02-28

Family

ID=43298181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011013060A MX2011013060A (es) 2009-06-05 2010-06-04 Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.

Country Status (6)

Country Link
US (1) US20100311688A1 (es)
EP (1) EP2437602A4 (es)
JP (1) JP2012528888A (es)
CA (1) CA2764477A1 (es)
MX (1) MX2011013060A (es)
WO (1) WO2010141831A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534313B1 (en) 2002-07-30 2012-10-17 Omeros Corporation Ophthalmologic irrigation solutions and method
EP2595625B1 (en) * 2010-07-22 2016-04-20 Ramot at Tel-Aviv University Ltd. Pharmaceutical composition containing a tryptophan derivative
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
JP2013542838A (ja) 2010-11-16 2013-11-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドライアイを治療するためのシステムおよび方法
WO2012098653A1 (ja) * 2011-01-19 2012-07-26 株式会社メニコン コンタクトレンズ用液剤
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
KR102276326B1 (ko) 2013-03-13 2021-07-13 앙테이스 에스.아. 피부 회춘을 위한 펩타이드 및 이것을 사용하는 방법
NZ704579A (en) 2013-04-19 2018-10-26 Oculeve Inc Nasal stimulation devices and methods
EP2999775A4 (en) * 2013-05-23 2016-06-08 Smm Ventures Llc SKLERALLINSENSLÖSUNG
CN106470673B (zh) 2014-02-25 2020-01-31 奥库利维公司 用于鼻泪刺激的聚合物制剂
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
EP3673952A1 (en) 2014-07-25 2020-07-01 Oculeve, Inc. Stimulation patterns for treating dry eye
AU2015335776B2 (en) 2014-10-22 2020-09-03 Oculeve, Inc. Stimulation devices and methods for treating dry eye
US9764150B2 (en) 2014-10-22 2017-09-19 Oculeve, Inc. Contact lens for increasing tear production
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
WO2017192572A1 (en) 2016-05-02 2017-11-09 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
CN109689161A (zh) 2016-08-19 2019-04-26 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法以及用于治疗人眼的组合物
RU2019118600A (ru) * 2016-12-02 2021-01-11 Окулив, Инк. Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению
CN110461350A (zh) * 2017-02-21 2019-11-15 缇尔索卢森公司 稳定的肽组合物
KR20200018580A (ko) * 2017-06-08 2020-02-19 아이 쎄러피스 엘엘씨 저용량 브리모니딘 조합 및 그의 용도
US20190374537A1 (en) * 2018-06-07 2019-12-12 Eye Therapies, Llc Low-dose brimonidine combinations and uses thereof
EP3668474A4 (en) 2017-08-18 2021-05-26 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN113712907A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种盐酸左西替利嗪滴眼液组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096733A (en) * 1998-12-10 2000-08-01 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US7658947B2 (en) * 2004-06-25 2010-02-09 Kimberly-Clark Worldwide, Inc. Thermo-gelling composition
US20080039398A1 (en) * 2006-01-25 2008-02-14 Ousler George W Iii Formulations and methods for treating dry eye
US20100239518A1 (en) * 2007-09-14 2010-09-23 Yasuko Matsumura Ophthalmic composition

Also Published As

Publication number Publication date
US20100311688A1 (en) 2010-12-09
CA2764477A1 (en) 2010-12-09
EP2437602A1 (en) 2012-04-11
WO2010141831A1 (en) 2010-12-09
JP2012528888A (ja) 2012-11-15
EP2437602A4 (en) 2014-02-19

Similar Documents

Publication Publication Date Title
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
EP4248971A3 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
MX2011013061A (es) Formulaciones oftalmicas de fluticasona y metodos de uso.
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
WO2007058935A3 (en) Ophthalmic composition for dry eye therapy
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
MX2013004061A (es) Analogos de ciclosporina.
JO3358B1 (ar) معالجات حساسية العيون
WO2012119070A3 (en) Silicone-based ophthalmic formulations
MX2017014245A (es) Composiciones que comprenden celulas germinales mesenquimales y usos de las mismas.
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
NZ755442A (en) Topical cyclosporine-containing formulations and uses thereof
MY150931A (en) Substituted oxazolidinones and their use
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
MX2013004062A (es) Analogos de ciclosporina.
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
PH12021550621A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal